Aguirre AJ. Refining Classification of Pancreatic Cancer Subtypes to Improve Clinical Care. Gastroenterology. 2018;155(6):1689-1691. doi:10.1053/j.gastro.2018.11.004.

Raghavan S, Winter PS, Navia AW, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021;184(25):6119-6137.e26. doi:10.1016/j.cell.2021.11.017.

Khalaf N, Yuan C, Hamada T, et al. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 2018;154(5):1380-1390.e5. doi:10.1053/j.gastro.2017.12.001.

Chen P-Y, Muzumdar MD, Dorans KJ, et al. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res. 2018;78(4):985-1002. doi:10.1158/0008-5472.CAN-17-2129.

Gilles M-E, Hao L, Huang L, et al. Personalized RNA Medicine for Pancreatic Cancer. Clin Cancer Res. 2018;24(7):1734-1747. doi:10.1158/1078-0432.CCR-17-2733.

Cejas P, Drier Y, Dreijerink KMA, et al. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019;25(8):1260-1265. doi:10.1038/s41591-019-0493-4.

Alvarez MJ, Subramaniam PS, Tang LH, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018;50(7):979-989. doi:10.1038/s41588-018-0138-4.

Danai LV, Babic A, Rosenthal MH, et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018;558(7711):600-604. doi:10.1038/s41586-018-0235-7.

Tian C, Huang Y, Clauser KR, et al. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells. Nat Commun. 2021;12(1):2328. doi:10.1038/s41467-021-22490-9.

Yuan C, Morales-Oyarvide V, Babic A, et al. Cigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017;35(16):1822-1828. doi:10.1200/JCO.2016.71.2026.